BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37851524)

  • 1. Unlocking the Mysteries of Chromatin Biology through Functional Epigenomics.
    Ye Z; Soshnev AA; Soto-Feliciano Y
    Cancer Res; 2023 Dec; 83(24):4010-4012. PubMed ID: 37851524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-ChIP reveals selective regulation of H3K79me2 by Menin in MLL leukemia.
    Gilan O; Talarmain L; Bell CC; Neville D; Knezevic K; Ferguson DT; Boudes M; Chan YC; Davidovich C; Lam EYN; Dawson MA
    Nat Struct Mol Biol; 2023 Oct; 30(10):1592-1606. PubMed ID: 37679565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
    Zhu L; Li Q; Wong SH; Huang M; Klein BJ; Shen J; Ikenouye L; Onishi M; Schneidawind D; Buechele C; Hansen L; Duque-Afonso J; Zhu F; Martin GM; Gozani O; Majeti R; Kutateladze TG; Cleary ML
    Cancer Discov; 2016 Jul; 6(7):770-83. PubMed ID: 27154821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
    Bernt KM; Zhu N; Sinha AU; Vempati S; Faber J; Krivtsov AV; Feng Z; Punt N; Daigle A; Bullinger L; Pollock RM; Richon VM; Kung AL; Armstrong SA
    Cancer Cell; 2011 Jul; 20(1):66-78. PubMed ID: 21741597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated transcriptomic and epigenetic data analysis identifiesaberrant expression of genes in acute myeloid leukemia with MLL‑AF9 translocation.
    Wang F; Li Z; Wang G; Tian X; Zhou J; Yu W; Fan Z; Dong L; Lu J; Xu J; Zhang W; Liang A
    Mol Med Rep; 2020 Feb; 21(2):883-893. PubMed ID: 31789407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 Di- and tri-methylation on target genes and transformation potential.
    Kuntimaddi A; Achille NJ; Thorpe J; Lokken AA; Singh R; Hemenway CS; Adli M; Zeleznik-Le NJ; Bushweller JH
    Cell Rep; 2015 May; 11(5):808-20. PubMed ID: 25921540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
    Nguyen AT; Taranova O; He J; Zhang Y
    Blood; 2011 Jun; 117(25):6912-22. PubMed ID: 21521783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic strategies against hDOT1L as a potential drug target in MLL-rearranged leukemias.
    Banday S; Farooq Z; Ganai SA; Altaf M
    Clin Epigenetics; 2020 May; 12(1):73. PubMed ID: 32450905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.
    Yang L; Liu L; Gao H; Pinnamaneni JP; Sanagasetti D; Singh VP; Wang K; Mathison M; Zhang Q; Chen F; Mo Q; Rosengart T; Yang J
    J Hematol Oncol; 2017 Oct; 10(1):159. PubMed ID: 28974232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.
    Wang E; Kawaoka S; Yu M; Shi J; Ni T; Yang W; Zhu J; Roeder RG; Vakoc CR
    Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3901-6. PubMed ID: 23412334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of DOT1L in the maintenance of leukemia gene expression.
    Wang X; Chen CW; Armstrong SA
    Curr Opin Genet Dev; 2016 Feb; 36():68-72. PubMed ID: 27151433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
    Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
    Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia.
    Risner LE; Kuntimaddi A; Lokken AA; Achille NJ; Birch NW; Schoenfelt K; Bushweller JH; Zeleznik-Le NJ
    J Biol Chem; 2013 Oct; 288(41):29901-10. PubMed ID: 23990460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
    Deshpande AJ; Chen L; Fazio M; Sinha AU; Bernt KM; Banka D; Dias S; Chang J; Olhava EJ; Daigle SR; Richon VM; Pollock RM; Armstrong SA
    Blood; 2013 Mar; 121(13):2533-41. PubMed ID: 23361907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells.
    Steger DJ; Lefterova MI; Ying L; Stonestrom AJ; Schupp M; Zhuo D; Vakoc AL; Kim JE; Chen J; Lazar MA; Blobel GA; Vakoc CR
    Mol Cell Biol; 2008 Apr; 28(8):2825-39. PubMed ID: 18285465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation.
    Balbach ST; Orkin SH
    Cancer Discov; 2016 Jul; 6(7):700-2. PubMed ID: 27371576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
    Lillico R; Lawrence CK; Lakowski TM
    J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription.
    Chang PY; Hom RA; Musselman CA; Zhu L; Kuo A; Gozani O; Kutateladze TG; Cleary ML
    J Mol Biol; 2010 Jul; 400(2):137-44. PubMed ID: 20452361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape.
    Olsen SN; Godfrey L; Healy JP; Choi YA; Kai Y; Hatton C; Perner F; Haarer EL; Nabet B; Yuan GC; Armstrong SA
    Mol Cell; 2022 Mar; 82(6):1140-1155.e11. PubMed ID: 35245435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.
    Geng H; Brennan S; Milne TA; Chen WY; Li Y; Hurtz C; Kweon SM; Zickl L; Shojaee S; Neuberg D; Huang C; Biswas D; Xin Y; Racevskis J; Ketterling RP; Luger SM; Lazarus H; Tallman MS; Rowe JM; Litzow MR; Guzman ML; Allis CD; Roeder RG; Müschen M; Paietta E; Elemento O; Melnick AM
    Cancer Discov; 2012 Nov; 2(11):1004-23. PubMed ID: 23107779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.